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Abstract 
Background: No study evaluated vascular health markers in subjects with non-alcoholic fatty liver disease (NAFLD) 
through a combined analysis of reactive hyperemia peripheral arterial tonometry (RH-PAT) and arterial stiffness 
indexes.
Aim of the study: We aimed to assess whether NAFLD and its histological severity are associated with impairment of 
arterial stiffness and RH-PAT indexes in a mixed cohort of patients with biopsy-proven NAFLD.
Materials and methods: The Kleiner classification was used to grade NAFLD grade. Pulse wave velocity (PWV) 
and augmentation index (Aix) were used as markers of arterial stiffness, whereas endothelial function was assessed 
using reactive hyperemia index (RHI). The mini-mental state examination (MMSE) was administered to test cognitive 
performance.
Results: 80 consecutive patients with biopsy-proven NAFLD and 83 controls without fatty liver disease. NAFLD 
subjects showed significantly lower mean RHI, higher mean arterial stiffness indexes and lower mean MMSE score. 
Multivariable analysis after correction for BMI, dyslipidaemia, hypertension, sex, diabetes, age and cardiovascular dis-
ease showed that BMI, diastolic blood pressure and RHI are significantly associated to NAFLD. Simple linear regression 
analysis showed among non-alcoholic steatohepatitis (NASH) subjects a significant negative relationship between 
ballooning grade and MMSE and a significant positive association between Kleiner steatosis grade and augmentation 
index.
Conclusions: Future research will be addressed to evaluate the relationship between inflammatory markers and 
arterial stiffness and endothelial function indexes in NAFLD subjects. These study will evaluate association between 
cardiovascular event incidence and arterial stiffness, endothelial and cognitive markers, and they will address the ben-
eficial effects of cardiovascular drugs such as statins and ACE inhibitors on these surrogate markers in NAFLD subjects.
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Introduction
Liver is a target organ in metabolic syndrome (MS) 
patients in which it manifests itself with non-alcoholic 
fatty liver disease (NAFLD) spanning steatosis via steato-
hepatitis and cirrhosis (1.2). Non-alcoholic fatty liver dis-
ease and non-alcoholic steatohepatitis (NASH) have been 
reported as associated with cardiovascular events [1–3].
Several useful surrogates in the clinical setting include 
Framingham Risk Score, carotid artery intima-media 
thickness, high sensitivity C-reactive protein (hsCRP), 
visceral and mediastinal fat, and coronary calcium scores 
[4, 5].
Forearm flow-mediated vasodilation (FMD) is a com-
monly used method for the assessment of endothe-
lial dysfunction [6]. However, findings offered by FMD 
can be very different owing to technical issues thus this 
method has been reported as not standardized [7].
Reactive hyperemia peripheral arterial tonometry (RH-
PAT) is a new method useful to measure endothelial dys-
function that has been reported by Kuvin et al. [8]. This 
method is noninvasive, and quantitative and it offers a 
digital measurement of hyperemic response. Framing-
ham Heart Study reported that reactive hyperemia index 
(RHI) is inversely correlated with various cardiovascular 
risk factors [9].
Adjunctive surrogates for cardiovascular risk more 
recently validated by some studies [10, 11] are arterial 
stiffness and endothelial function indexes.
Augmentation pressure and pulse wave velocity (PWV) 
have been reported as surrogate markers for cardiovascu-
lar disease [10]. They are both two markers of endothelial 
dysfunction and vascular damage [11] and some studies 
analyzed arterial stiffness indexes in NAFLD patients 
[12–14].
Vlachopoulos et al. [12] reported that NAFLD subjects 
showed significantly higher carotid-femoral pulse wave 
velocity and reduced flow-mediated dilatation (FMD) 
and that at multivariable analysis, presence of NAFLD 
was an independent determinant of both PWV and FMD. 
In another study Salvi et  al. [13] reported that patients 
with NAFLD and MS PWV values were significantly 
higher in comparison to controls and to NAFLD subjects 
without MS.
Nonetheless, only a study [15] analyzed endothelial 
dysfunction in these subjects using flow mediated dila-
tion and flow-mediated vasoactivity (FMV) findings. 
Authors reported that NAFLD was associated with a 
percent FMV in the lower tertile after adjustment for 
age, sex, body mass index, and insulin resistance and that 
among NAFLD patients, low FMV was associated with 
nonalcoholic steatohepatitis.
Vascular disease seems to be important in cognitive 
impairment and cerebrovascular disease, including white 
matter lesions and silent infarcts that may lead to a spe-
cific pattern of cognitive impairment. It explains that 
cognitive function indexes such as mini-mental state 
examination (MMSE) scores could be putative to be con-
sidered a surrogate vascular marker.
Thus, the evaluation by means the analysis of RH-PAT 
indexes, arterial stiffness markers and cognitive perfor-
mance could offer a more complete and useful informa-
tion with regard of the vascular health status of NAFLD 
patients.
No study, to the best of our knowledge, has analyzed 
endothelial dysfunction in subjects with NAFLD through 
an analysis of RH-PAT indexes. Furthermore no study 
analyzed the relationship between histological severity 
of NAFLD and arterial stiffness and RH-PAT indexes and 
no study evaluated cognitive indexes as surrogate vas-
cular markers in association with other surrogate mark-
ers such as arterial stiffness and endothelial function 
indexes, whereas only one study evaluated the relation-
ship between cognitive function and NAFLD [14].
Considering the link between NAFLD, its related 
metabolic changes and cardiovascular risk, to assess 
whether NAFLD and its histological severity is related 
to the impairment of some surrogate markers of vascular 
impairment, we designed a study with a principal aim:
1. To evaluate arterial stiffness and RH-PAT indexes 
in a mixed cohort of patients with biopsy-proven 
NAFLD in comparison with subjects without fatty 
liver and with regard to NASH presence; and two 
secondary aims:
2. To evaluate cognitive performance measured by 
MMSE in a mixed cohort of patients with biopsy-
proven NAFLD in comparison with subjects without 
fatty liver and with regard to NASH presence;
3. To analyze the relationship between hepatic histo-
logical findings of NAFLD and surrogate markers of 
vascular impairment (arterial stiffness and RH-PAT 
indexes and cognitive performance index).
Patients and methods
Patients
We recruited all NAFLD patients admitted to the Gas-
trointestinal & Liver Unit of Palermo University Hospital 
from June 2014 to December 2015.
Inclusion criteria were: (1) a histological diagnosis of 
NAFLD on a liver biopsy obtained less than 6  months 
before enrollment.
A pre-biopsy evaluation of NAFLD was based on these 
findings: increased serum levels of alanine transaminase 
(ALT) for at least 6  months and alcohol consumption 
of  <  20  g/day in the previous year (also confirmed by a 
questionnaire). Liver ultrasound was performed in all 
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groups (study group and control) and patients were also 
recruited by ultrasound (US) finding of steatosis, and a 
liver stiffness value > 6 kPa.
Exclusion criteria were: (1) steatosis, (2) decom-
pensated cirrhosis; (3) hepatocellular carcinoma; (4) 
liver disease of different or mixed etiology (alcoholic, 
viral, autoimmune Wilson’s disease, hemochromatosis, 
α1-antitrypsin deficiency); (5) human immunodeficiency 
virus infection; [6] regular use of steatosis-inducing drugs 
(steroid, amiodarone, tamoxifen, etc.).
Subjects without NAFLD were referred from gen-
eral practitioners or they were recruited among patients 
admitted to Internal Medicine and Stroke Care ward 
of Policlinico Universitario “P. Giaccone”, University of 
Palermo, Italy. All the subjects enrolled as controls had 
no history of previous cardiovascular or cerebrovascu-
lar disease or metabolic disease or acute disease such as 
acute myocardial infarction (AMI) or stroke or infections 
or deep venous thrombosis. They were metabolic and 
cardiovascular disease free subjects referred from general 
practioners or admitted to our department for another 
disease else those indicated as exclusion criteria in the 
same period.
Among 209 that were evaluated, 120 had no steatosis 
but satisfied all the criteria indicated above. They had 
no previous history of previous cardiovascular events, 
no history of liver disease, no evidence of viral infec-
tion (anti-HCV, anti-HIV, and HBsAg negativity), alco-
hol consumption  >  20  g/day during the previous year 
(evaluated by a specific questionnaire), normal alanine 
transaminase values (< 37 UI/l), no ultrasound (US) find-
ing of steatosis, and a liver stiffness value < 6 kPa.
Consent for publication
All enrolled patients released a consent to publish from 
the participant (or legal parent or guardian for children) 
to report individual patient data.
Availability of data and material
All data and material are available on figshare.
Clinical and laboratory assessment
Clinical and anthropometric data were collected at 
the time of enrollment. Subjects were classified as nor-
mal weight (BMI 18.5–24.9  kg/m2), overweight (BMI 
25–29.9), obese (BMI  ≥  30). The diagnosis of arterial 
hypertension was based on the following criteria: systolic 
blood pressure ≥ 140 mmHg and/or diastolic blood pres-
sure ≥ 90 mmHg (measured three times within 30 min, 
in the sitting position and using a brachial sphygmoma-
nometer), or use of blood-pressure-lowering agents [16]. 
The diagnosis of type 2 diabetes was based on the revised 
criteria of the American Diabetes Association, using 
a value of fasting blood glucose  ≥  126  mg/dl [17]. In 
patients with a previous diagnosis of type 2 diabetes, cur-
rent therapy with insulin or oral hypoglycemic agents was 
documented. A 12-h overnight fasting blood sample was 
drawn at the time of enrollment to determine the serum 
levels of ALT, total cholesterol, HDL-cholesterol, triglyc-
erides, plasma glucose, insulin (for NAFLD only), and 
platelet count (for NAFLD). Dyslipidemia was defined as 
Triglyceride (TG) level ≥ 150 mg/dl and total cholesterol 
levels  >  200  mg/dl. We also performed HDL-levels cat-
egorization according to a gender-specific threshold for 
HDL (40 mg/dl for male and 50 mg/dl for females) [18].
Ultrasound assessment
Ultrasound assessment was performed on fasting sub-
jects, on the day of liver biopsy for NAFLD, and on the 
day of enrollment of the controls, by one operator trained 
in ultrasound techniques and dedicated to liver examina-
tion. A real-time Hitachi H21 apparatus with a 2–5 MHz, 
convex, multi-frequency probe was used. Presence of 
hepatic steatosis was defined by detection of Bright Liver 
Echo pattern (BLEP), i.e. fine, packed and high amplitude 
echoes, with consequent brightness of liver, increase in 
liver–kidney contrast and possible evidence of vascular 
blurring and deep attenuation signs [19].
Liver stiffness measurement (LSM)
Transient elastography was performed with the FibroS-
can (Echosens, Paris, France) medical device, using the 
M probe (also called standard probe), following the ultra-
sound examination, by trained operators who had previ-
ously performed at least 300 determinations in patients 
with chronic liver disease. As recently reported in the lit-
erature [20], we classified LSM examinations into three 
reliability categories: “very reliable” (IQR/M  ≤  0.10), 
“reliable” (0.10  <  IQR/M  ≤  0.30, or IQR/M  >  0.30 
with LSM median  <  7.1  kPa), and “poorly reliable” 
(IQR/M > 0.30 with LSM median ≥ 7.1 kPa). “Poorly reli-
able” results were excluded from the analysis.
Assessment of histology
Slides of NAFLD were coded and read by one patholo-
gist (D.C.), who was unaware of the patients’ identity and 
history. A minimum length of 15 mm of biopsy specimen 
or the presence of at least 10 complete portal tracts was 
required [21]. Steatosis was assessed as the percentage of 
hepatocytes containing fat droplets (minimum 5%), and 
evaluated as a continuous variable. The Kleiner classifica-
tion [22] was used to grade steatosis, lobular inflamma-
tion, and hepatocellular ballooning, and to stage fibrosis 
from 0 to 4 [23]. NASH was considered to be present 
when steatosis, ballooning, and lobular inflammation 
were present.
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Pulse wave velocity (PWV) measurement
Carotid-femoral PWV was measured in the supine posi-
tion using an automatic device (SphygmoCor version 
7.1) that measured the time delay between the rapid 
upstroke of the carotid and femoral artery pulse waves. 
The distance between the 2 arterial points was measured 
on the surface of the body using a tape measure. PWV 
was calculated as the distance traveled by the arterial 
pulse wave (meters) divided by the time delay between 
the 2 arterial points (seconds), thus expressed as meters 
per second.
Pulse wave analysis
Applanation tonometry was used to record radial artery 
pressure waveform continuously, and mean values of ≥ 2 
screens of pulse waves of good quality were used for 
analysis. From the collected data, an averaged radial pres-
sure waveform was generated and a corresponding aortic 
pressure waveform and BP was calculated by the vali-
dated transfer function (SphygmoCor version 7.1). The 
aortic pressure waveform was used to calculate the AIx 
(difference in height between the first and second systolic 
peaks expressed as a percentage of PP).
RH‑PAT
The principle of RH-PAT has been described previously 
by some researchers [15]. Briefly, blood pressure cuff 
was placed on 1 upper arm, while the contralateral arm 
served as a control. PAT probes were placed on 1 finger 
of each hand. After a 5 min equilibration period, the cuff 
was inflated to 60 mmHg above the systolic pressure or 
200 mmHg for 5 min and then deflated to induce reactive 
hyperemia.
The RH-PAT data were digitally analyzed online (Endo-
PAT2000 software version 3.0.4). The RH-PAT index 
reflects the extent of reactive hyperemia and was calcu-
lated as the ratio of the average amplitude of PAT signal 
over 1  min starting 1.5  min after cuff deflation (control 
arm, A; occludedarm, C) divided by the average ampli-
tude of PAT signal of a 2.5  min time period before cuff 
inflation (baseline) (control arm, B; occluded arm, D). 
Thus RH-PAT index (RHI)  =  (C/D)/(A/B)  ×  baseline 
correction.
Assessment of cognitive function (mini‑mental state 
examination)
The mini-mental state examination (MMSE) a tool that can 
be used to systematically and thoroughly assess cognitive 
function was administered. It is an 11-question measure 
that tests 5 areas of cognitive function (orientation, regis-
tration, attention and calculation, recall, and language). The 
maximum score is 30 whereas an MMSE value < 24 (23 or 
lower) is indicative of cognitive impairment [24].
Statistical analysis
Statistical analysis of quantitative and qualitative data, 
including descriptive statistics, was performed for all 
items. Continuous data are expressed as mean  ±  SD, 
unless otherwise specified. Baseline differences between 
groups were assessed by the Chi square test or Fisher 
exact test, as needed for categorical variables, and by the 
independent Student t test for continuous parameters.
The analysis of variance (ANOVA) was performed for 
parametric variables in univariable and multivariable 
model to evaluate the difference between NASH vs no 
NASH patients. In both models the data were adjusted 
for BMI, dyslipidaemia, hypertension, sex, diabetes, car-
diovascular disease and age.
Simple linear regression analysis was used to assess his-
tological hepatic damage markers (Kleiner classification 
indexes) independently associated with vascular damage 
indexes in NASH and no NASH patients, respectively. B 
coefficients (B) and their 95% confidence intervals (CIs) 
were also calculated and adjusted for BMI, dyslipidae-
mia, hypertension, sex, diabetes, cardiovascular disease 
and age. In the model, the dependent variables were RHI, 
PWV, Aix and MMSE. Data were analyzed by the SPSS 
Software 22.0 version (IBM Corp., Armonk, NY, USA). 
All p-values were two-sided, and p-values less than 0.05 
were considered statistically significant.
Results
The study involved 80 consecutive patients with biopsy-
proven NAFLD and 83 controls without a fatty liver dis-
ease. General and laboratory variables of patients with 
NAFLD and controls are listed in Table 1.
NAFLD subjects in comparison to controls had a 
higher BMI (28.7 ± 5.6 vs. 25.3 ± 3.8; p = 0.005) and liver 
stiffness (9.37 ± 7.7 vs 4.5 ± 0.4 kPa) and they were more 
likely to have hypertension (35% vs. 15.7%; p  =  0.006) 
and diabetes (38.8% vs. 8.4%, p = 0.005).
NAFLD subjects in comparison to controls also had a 
significantly lower mean RHI (1.85 ± 0.5 vs. 2.20 ± 0.6; 
p  =  0.005) and higher mean arterial stiffness indexes 
such as Aix (144.3 ± 27.2 vs. 131.4 ± 31.4, p = 0.006) and 
PWV (10.46 ± 2.1 m/s vs. 9.61 ± 2.30 m/s; p = 0.015). 
MMSE was available for 139 patients (74 with and 65 
without NAFLD), with similar characteristics compared 
to the entire cohort (data not shown).
NAFLD patients had a lower mean MMSE score 
(26.9 ± 1.6 vs. 28.0 ± 1.36; p = 0.005) in comparison with 
patients without NAFLD.
At univariable analysis we observed a significant rela-
tionship between BMI (p = 0.004), diastolic blood pres-
sure (p =  0.019), Aix (p =  0.018), MMSE (p  <  0.0001), 
RHI (p  =  0.007) and NAFLD, whereas at multivari-
able analysis after correction for BMI, dyslipidaemia, 
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hypertension, sex, diabetes and age and cardiovascular 
disease only BMI (p  =  0036), diastolic blood pressure 
(p  =  0.048), MMSE (p  <  0.0001) and RHI (p  =  0.032) 
remained significantly associated to NAFLD (see 
Table 2).
In NAFLD subjects we observed no significant differ-
ence with regard to vascular damage markers and MMSE 
score accordingly to NASH presence or absence (see 
Table 3).
In NAFLD subjects we also observed no significant 
difference with regard of vascular damage markers an 
MMSE score accordingly to fibrosis severity (see Table 4).
At simple linear regression, after correction for BMI, 
dyslipidaemia, hypertension, sex, diabetes, age and car-
diovascular disease, analysis of the relationship between 
hepatic histological findings and vascular damage mark-
ers, showed a significant negative relationship linking 
MMSE and Kleiner ballooning grade [B = − 1.344 (95% 
CI = − 2.650 to 0.037); p = 0.044] and a significant posi-
tive relationship linking Aix and Kleiner steatosis grade 
[B = 4.957 (95% CI = 1.385–8.529); p = 0.008] in NAFLD 
subjects with NASH (see Table 5).
No significant relationship was observed between 
hepatic histological findings and vascular damage mark-
ers among NAFLD subjects without NASH.
Discussion
In a mixed cohort of patients with NAFLD and controls 
without fatty liver, we report that subjects with NAFLD 
had significantly lower RHI values and higher mean 
arterial stiffness indexes such as Aix and PWV, and that 
NAFLD subjects also had lower mean MMSE scores in 
comparison with control subjects without NAFLD.
To the best of our knowledge, no study has yet 
addressed the relationship between endothelial 
Table 1 Demographic, laboratory and clinical variables 
in NAFLD subjects and controls
Liver stiffness: measured by transient elastography (TE) (fibroscan)
Significant p values are indicated in Italics
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, 
Aix: augmentation index, PWV pulse wave velocity, RHI reactive hyperemia index, 
MMSE mini-mental state examination, kPa kilopascal
Variable NAFLD subjects 
(n = 80)
Controls 
(n = 83)
p
Age (years) (mean ± SD) 53.7 ± 12.9 51.7 ± 17.2 0.401
Weight (kg) (mean ± SD) 78.9 ± 17.7 71.3 ± 13.4 0.002
BMI (kg/m2) (mean ± SD) 28.7 ± 5.6 25.3 ± 3.8 0.005
SBP (mm/Hg) (mean ± SD) 121.7 ± 13.7 122.7 ± 16.3 0.655
DBP (mm/Hg) (mean ± SD) 72.7 ± 9.5 75.4 ± 12.7 0.127
Hypertension (n/%) 28 (35.0) 13 (15.7) 0.006
Diabetes (n/%) 31 (38.8) 7 (8.4) 0.005
Dyslipidaemia (n/%) 15 (18.8) 14 (16.9) 0.839
Previous cardiovascular 
diseases
3 (3.75) 0 0.341
Previous cerebrovascular 
events
0 0 0.417
RHI (mean ± SD) 1.85 ± 0.5 2.20 ± 0.6 0.005
Aix (%) (mean ± SD) 144.3 ± 27.2 131.4 ± 31.4 0.006
PWV (mt/s) (mean ± SD) 10.46 ± 2.1 9.61 ± 2.30 0.015
MMSE (mean ± SD) 26.9 ± 1.6 28.0 ± 1.4 0.005
Liver stiffness, kPa 9.37 ± 7.7 4.5 ± 0.4 0.005
NASH patients (n/%) 52
Histology (%) 52 (65)
Kleiner steatosis grade 0–3 (mean/SD)
 1 (n/%) 36 (45)
 2 (n/%) 22 (27.5)
 3 (n/%) 22 (27.5)
Lobular inflammation grade 0–3 (mean/SD)
 0 (n/%) 2 (2.5)
 1 (n/%) 45 (56.3)
 2 (n/%) 31 (38.8)
 3 (n/%) 2 (2.5)
Hepatocellular ballooning 0–2 (mean/SD)
 0 (n/%) 23 (28.7)
 1 (n/%) 35 (43.8)
 2 (n/%) 22 (27.5)
Stage of fibrosis (0–4) (mean/SD)
 0 (n/%) 18 (22.5)
 1 (n/%) 25 (31.3)
 2 (n/%) 14 (17.5)
 3 (n/%) 17 (21.3)
 4 (n/%) 6 (7.5)
Table 2 Univariate and multivariate analysis of relation-
ship between clinical variables and NAFLD
Adjusted for BMI, dysilipidaemia, hypertension, sex, diabetes and age
Significant p values are indicated in Italics
Dependent variables F Sign.
Univariable analysis
 Age 0.011 0.915
 BMI 8.452 0.004
 SBP 3.854 0.051
 DBP 5.581 0.019
 Aix 5.751 0.018
 PWV 2.223 0.138
 MMSE 20.069 < 0.0001
 RHI 7.423 0.007
Multivariable analysis
 BMI 4.512 0.036
 SBP 3.688 0.057
 DBP 3.977 0.048
 Aix 1.615 0.206
 MMSE 24.999 <0.0001
 RHI 4.722 0.032
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dysfunction markers evaluated by reactive hyperemia 
peripheral arterial tonometry (RH-PAT) and NAFLD. 
Some studies analyzed arterial stiffness indexes in sub-
jects with NAFLD [25–27] and just one study evaluated 
cognitive performance in NAFLD patients [28]. Thus, our 
findings of impaired vascular damage markers in subjects 
with NAFLD could appear as novel.
The study by Leite et  al. [25] showed that diabetic 
patients with NAFLD are more likely to have high or 
increasing aortic stiffness that predicted the development 
of advanced liver fibrosis transient elastography. The 
study by Sunbul et al. [27] analyzed patients with biopsy-
proven NAFLD whereas the study by Seo et al. [28] ana-
lyzed subjects with ultrasound defined NAFLD.
In particular the study of Sunbul [27] showed that 
NAFLD patients compared with controls, had signifi-
cantly higher PWV and AIx values. Nevertheless, in this 
previous study authors analyzed the relationship between 
Table 3 Clinical variables of NAFLD patients according to NASH presence
Significant p values are indicated in Italics
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, Aix: augmentation index, PWV pulse wave velocity, RHI reactive hyperemia index, 
MMSE mini-mental state examination, kPa kiloPascal
Variable No NASH subjects (n = 28) NASH subjects (n = 52) p
Age (years) (mean ± SD) 51.5 ± 12.8 54.9 ± 12.8 0.258
Weight (kg) (mean ± SD) 78.6 ± 19.9 79.3 ± 15.3 0.850
BMI (kg/m2) (mean ± SD) 27.6 ± 6.3 29.3 ± 5.1 0.812
SBP (mm/Hg) (mean ± SD) 120.1 ± 13.1 122.5 ± 14.1 0.443
DBP (mm/Hg) (mean ± SD) 72.3 ± 9.6 72.9 ± 9.6 0.771
Gender M/F 15/13 25/27 0.815
Hypertension (n/%) 8 (28.6) 20 (38.5) 0.464
Diabetes (n/%) 9 (32.1) 22 (42.3) 0.472
Dyslipidaemia (n/%) 4 (14.3) 11 (21.1) 0.557
Previous cardiovascular diseases 0(0) 3 (5.8) 0.309
Previous cerebrovascular events 0 0 /
RHI (mean ± SD) 1.8 ± 0.51 1.9 ± 0.52 0.670
Aix (%) (mean ± SD) 141.1 ± 25.4
26.8 ± 12.3
146.1 ± 28.1
29.6 ± 12.2
0.338
0.429
PWV (mt/s) (mean ± SD) 10.4 ± 1.9 10.4 ± 2.2 0.971
MMSE (mean ± SD) 27.5 ± 2.0 27.3 ± 2.9 0.765
Liver stiffness, kPa 6.7 ± 2.7 11.5 ± 8.0 0.003
Histology (%)
Kleiner steatosis grade 0–3
 1 (n/%) 16 (57.1) 20 (38.5)
 2 (n/%) 7 (25.0) 15 (28.8) 0.271
 3 (n/%) 5 (17.9) 17 (32.7)
Lobular inflammation grade 0–3
 0 (n/%) 2 (7.1) 0
 1 (n/%) 23 (82.1) 22 (42.3)
 2 (n/%) 2 (7.1) 29 (55.8) < 0.0001
 3 (n/%) 1 (3.6) 1 (1.9)
Hepatocellular ballooning (0–2)
 0 (n/%) 11 (39.3) 12 (23.1)
 1 (n/%) 15 (53.6) 20 (38.4) 0.010
 2 (n/%) 2 (7.1) 20 (38.4)
Stage of fibrosis (0–4)
 0 (n/%) 11 (39.3) 7 (13.5)
 1 (n/%) 14 (50.0) 11 (21.1)
 2 (n/%) 3 (10.7) 11 (21.1) < 0.0001
 3 (n/%) 0 17 (32.7)
 4 (n/%) 0 6 (11.5)
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Table 4 Clinical variables of NAFLD patients according to NASH and severity of fibrosis
Significant p values are indicated in Italics
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, Aix augmentation index, PWV pulse wave velocity, RHI reactive hyperemia index, 
MMSE mini-mental state examination, kPa kiloPascal
Variable Subjects with fibrosis 0–1 (n = 43) Subjects with fibrosis ≥ 2 (n = 37) p
Age (years) (mean ± SD) 50.2 ± 11.9 57.8 ± 12.9 0.008
Weight (kg) (mean ± SD) 75.3 ± 14.0 83.2 ± 20.4 0.045
BMI (kg/m2) (mean ± SD) 27.4 ± 5.1 30.3 ± 5.7 0.017
SBP (mm/Hg) (mean ± SD) 117.8 ± 11.7 126.2 ± 14.6 0.006
DBP (mm/Hg) (mean ± SD) 71.9 ± 8.4 73.6 ± 10.8 0.440
Gender M/F 24/19 16/21 0.262
Hypertension (n/%) 11 (25.6) 17 (45.9) 0.057
Diabetes (n/%) 10 (23.3) 21 (56.8) 0.002
dyslipidemia (n/ %) 7 (16.3) 8 (21.6) 0.542
Previous cardiovascular diseases 0 (0) 3 (8.1) 0.057
Previous cerebrovascular events 0 0 /
RHI (mean ± SD) 1.9 ± 0.54 1.8 ± 0.47 0.211
Aix (%) 139.8 ± 29.4 149.7 ± 23.6 0.103
(mean ± SD) 25.8 ± 13.2 31.9 ± 10.4 0.027
PWV (mt/s) (mean ± SD) 10.0 ± 1.9 10.9 ± 2.3 0.043
MMSE (mean ± SD) 27.8 ± 2.2 26.9 ± 2.9 0.131
Liver stiffness, kPa 7.5 ± 3.6 12.6 ± 8.9 0.001
Histology (%)
 Kleiner steatosis grade 0–3
  1 (n/%) 29 (67.4) 7 (18.9)
  2 (n/%) 7 (16.3) 15 (40.5) < 0.0005
  3 (n/%) 7 (16.3) 15 (40.5)
 Lobular inflammation grade 0–3
  0 (n/%) 2 (4.6) 0
  1 (n/%) 36 (83.7) 9 (24.3)
  2 (n/%) 4 (9.3) 27 (73.0)  < 0.0005
  3 (n/%) 1 (2.3) 1 (2.7)
 Hepatocellular ballooning (0–2)
  0 (n/%) 21 (48.8) 2 (5.4)
  1 (n/%) 20 (46.5) 15 (40.5)  < 0.0005
  2 (n/%) 2 (4.6) 20 (54.0)
Table 5 Simple linear regression analysis of variables associated with vascular damage indexes (RHI, AIX, PWV 
and MMSE) in NAFLD subjects with and without NASH
Adjusted for BMI, dysilipidemia, hypertension, sex, diabetes and age and cardiovascular diseases
Vascular damage indexes Variable NASH No‑NASH
B (95% CI) p
PWV – – –
AIX Kleiner steatosis grade 4.957 (1.385 to 8.529) 0.008 –
RHI – – –
MMSE Kleiner balloning grade − 1.344 (− 2.650 to − 0.037) 0.044 –
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arterial stiffness indexes and only liver fibrosis scores. 
Thus, our current findings obtained after an analysis of 
the relationship between arterial stiffness indexes and the 
full range of hepatic histological changes in NAFLD sub-
jects may be considered a potential original result.
Endothelial dysfunction is one of the earliest events in 
the pathogenetic process leading to the atherosclerotic 
disorders [29], and it contributes to the progression of 
disease through inflammation and thrombosis [30–32].
Studies using the EndoPAT have shown that the RHI 
score reflects NO-bioavailability [33]. The RHI corre-
lates with the measurement of endothelial vasodilator 
function in the coronary arteries [34] and with brachial 
FMD [35]. Patients with a higher degree of cardiovascu-
lar involvement exhibit a lower score [36–38]. Notably, 
RHI values appear to be predictive of cardiovascular out-
comes [39–41].
Thus our findings of lower values of RHI in subjects 
with NAFLD may be suggestive of the raised cardiovas-
cular risk of patients with NAFLD due to a higher preva-
lence of endothelial dysfunction.
Multivariable analysis of association linking clinical 
variables and NAFLD showed the significant predictive 
role of RHI and MMSE. It is possible to speculate that 
endothelial dysfunction and impaired cognitive perfor-
mance may represent a potential hallmark of NAFLD and 
that endothelial function and cognitive markers could be 
employed as putative indicators of early vascular involve-
ment in this clinical context.
A recent study reported that NAFLD was indepen-
dently associated with lower cognitive performance inde-
pendent of CVD and its risk factors [14].
Our finding of lower MMSE values in subjects with 
NAFLD may be indicative of a lower degree of cognitive 
performance even in absence of MMSE scores indicating 
a clinical cognitive dysfunction, in subjects with higher 
degree of arterial stiffness and lower degree of endothe-
lial mediated vasodilation. Consistent with our findings a 
recent study [51] showed that a MMSE cut score to 27 
resulted in an optimal balance of sensitivity and speci-
ficity with an overall correct classification rate of 90% 
in a cognitively impaired group (dementia and MCI), 
thus indicating that a cut-score of 27 might be more 
appropriate.
Evidence from epidemiology and pathology studies 
indicates that damage to the vascular system is associ-
ated with an increased risk of many types of cognitive 
impairment [42–44]. Although we have not observed 
mean MMSE values indicating a cognitive dysfunction 
in both groups of subjects, our findings of lower MMSE 
mean scores observed in NAFLD patients (mean MMSE 
26.9) and the negative relationship observed between bal-
looning grade and MMSE may represent a further issue 
confirming the role of metabolic disturbances linked to 
NAFLD also in clinical setting of cognitive performance. 
Nevertheless, we observed no significant association 
between cognitive performance and histological find-
ings in NAFLD patients without NASH and only a sig-
nificant negative association between ballooning grade 
and MMSE in NAFLD subjects with NASH. This finding 
is novel since that no previous study has not yet reported 
any relation between histological severity of NAFLD and 
cognitive performance. Our group recently reported [44] 
that white matter lesions (WMLs) are not associated with 
the presence of NAFLD but with its histological severity. 
This finding may also suggest an alternative pathogenic 
hypothesis to explain subclinical lower cognitive perfor-
mance of NAFLD subjects such as small-artery remod-
eling and direct vascular cognitive impairment (VCI) well 
expressed by progressive arterial stiffening and endothe-
lial dysfunction [45–50]. These vascular changes are prob-
ably related to metabolic disorders underlying NAFLD 
presence.
Previous studies from our group reported an higher 
degree of organ damage expressed as the diabetic foot 
[51], a vascular impairment [52, 53] and the Obstructive 
Sleep Apnea syndrome (OSAS) [54] in subjects with MS.
Overweight and obesity and associated co-morbidities 
are established cardiovascular (CV) risk. Endothelial 
dysfunction (ED) is the initial vascular damage, which 
precedes fatty streak known to initiate atherosclerosis a 
progressive disease which often culminates as a sudden 
cardiovascular event [55].
Arterial stiffness and MS have been reported as asso-
ciated with cognitive impairment in elderly people. A 
recent study reported that age (older than 60 years) and 
MS play a synergistic role in cognitive decline pathogen-
esis in the elderly population [56].
Obstructive sleep apnea (OSA) and type 2 diabetes 
(T2D) are also associated with endothelial dysfunction 
[57], whereas increasing age, liver fat, and triglyceride are 
all related to increased aortic stiffness in adults [58] and 
a recent study indicates that NAFLD and MS have a syn-
ergistic impact on the subclinical atherosclerosis [59, 60].
Furthermore, a recent study reported that nonalcoholic 
fatty liver disease is associated with a smaller total cer-
ebral brain volume, indicating a possible link between 
hepatic steatosis and brain aging [61].
These factors may represent possible explanation of 
our findings of a higher degree of vascular impairment in 
subjects with NAFLD.
Our findings consistent with previous study [62] under-
lined that the reported higher degree of arterial stiffness 
in NAFLD patients compared with controls might be 
related to the higher prevalence of cardiometabolic risk 
factors in NAFLD patients.
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Thus, in NAFLD clinical setting liver and vessels repre-
sent parallel end-organ damage target of MS and insulin 
resistance.
This issue is furtherly confirmed by our findings about 
differences among NAFLD subjects in relation to NASH 
presence and fibrosis severity that showed no difference 
with regard of RHI and arterial stiffness markers in the 
two groups of subjects (NASH vs non NASH).
This is an interesting finding probably due to the fact 
the NAFLD subjects with NASH and those without 
NASH and subjects categorized in relation of fibrosis 
severity show similar prevalence of cardiovascular risk 
factors such as hypertension and diabetes and they also 
show not significant difference with regard of the mean 
value of arterial blood pressure and plasma cholesterol 
levels.
Nevertheless, although the presence of NASH does not 
seem significantly associated to a higher degree of vascu-
lar damage in patients with NAFLD our findings report 
a peculiar relationship between some histologic hepatic 
findings and vascular damage markers only in NASH 
subjects. Simple logistic regression analysis showed 
a negative association between ballooning grade and 
MMSE in NASH patients and a positive association has 
been observed in NASH subjects between steatosis grade 
and augmentation index.
Arterial stiffness is due to a complex interplay between 
dynamic or constant forces and structural and cellular 
components of the vascular wall such as hormones, salt 
and glucose aging and blood pressure [63, 64]. Resiliency 
and compliancy of the vascular wall depend on two pro-
teins: collagen and elastin. The presence of such mole-
cules in arterial wall is maintained by a constant interplay 
of production and degradation. An inflammatory milieu 
can trigger an impairment of this balance, driving to 
overproduction of altered collagen and impaired pres-
ence of elastin, leading to increased arterial stiffness [56]. 
Arterial hypertension and diabetes mellitus and ageing 
represent the main causes of these vascular alterations 
that worsen artery stiffening.
We observed no difference in main cardiovascular risk 
factor between NAFLD subjects with NASH and those 
without NASH, thus our findings of a significant rela-
tion between two histologic hepatic markers such as bal-
looning and steatosis grade could underline a possible 
prevalent role of a inflammatory milieu in arterial stiff-
ening and cerebral microvascular disease pathogenesis. 
Many studies evaluated if NAFLD contributed to other 
outcomes, such as cardiovascular mortality; and most of 
them demonstrated an association, but no causality could 
be shown [65–67]. In this light liver disease and athero-
genesis might be mediated by inflamed visceral adi-
pose tissue: In this pathogenetic scenario, nonalcoholic 
steatohepatitis and mainly NASH presence might be 
related to the presence of vascular disease in two ways: 
first, through the production of some inflammatory, pro-
thrombotic and oxidative-stress mediators and, second, 
by means the direct involvement of nonalcoholic fatty 
liver disease in insulin resistance mechanism and athero-
genic dyslipidemia.
Limitations
The main limitation of this study lies in its cross-sectional 
nature, unable to identify pathogenic mechanisms linking 
vascular damage and liver fibrosis. A further methodo-
logical question is the potentially limited external validity 
of the results for different populations and settings. Our 
study included a cohort of Italian NAFLD patients, largely 
obese, at high prevalence of NASH and severe fibrosis, 
who may be different, in terms of both metabolic features 
and severity of liver disease, from the majority of preva-
lent cases of NAFLD in the general population. The lack 
of data on a control Sicilian population might further 
limit the strength of our results; however higher preva-
lence of vascular damage in subjects with NAFLD seem to 
be a finding potentially applicable to other italian cohorts.
Another limitation is that our study included a cohort 
of Italian NAFLD patients referred to a tertiary referral 
center, largely obese, with abnormal ALT levels, and at 
high prevalence of NASH and severe fibrosis, who may 
be different, in terms of metabolic features, ALT levels 
and severity of liver disease, from the majority of preva-
lent cases of NAFLD in the general population”.
Finally, we also need data on serum levels and liver 
expression of proinflammatory and profibrogenic 
cytokines potentially involved in vascular changes of 
NAFLD patients.
Conclusions
This study reports that NAFLD subjects in comparison to 
controls without NAFLD had: (1) lower mean values of 
RHI; (2) higher mean values of PWV and Aix; (3) lower 
MMSE; (4) a significant relationship at multivariate anal-
ysis between RHI and MMSE with NAFLD, (5) a signifi-
cant negative relationship between ballooning grade and 
MMSE grade only in NASH subjects; (6) a significant 
positive relationship between steatosis and augmentation 
index only in NASH subjects.
Several previous studies [54–56] pinpointed the 
inflammatory background of nonalcoholic fatty liver dis-
ease, thus future studies will be addressed to evaluate the 
relationship between inflammatory markers and arte-
rial stiffness and endothelial function indexes in NAFLD 
subjects.
Future research could address these issues both by 
means of longitudinal studies to evaluate incidence of 
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new-onset cardiovascular events and their connection 
with arterial stiffness, endothelial and cognitive mark-
ers. They also should analyze the beneficial effects of 
cardiovascular drugs such as statins and ACE inhibitors 
on these surrogate markers (indicators of arterial stiff-
ness, endothelial function and cognitive performance) in 
NAFLD subjects.
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